Analyst Research

Report Title Price
Provider: GlobalData
Provider: S&P Capital IQ Quantitative Report
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Aeterna Zentaris Inc NDA for Macimorelin Acetate in AGHD accepted for filing by the FDA

Monday, 6 Jan 2014 12:00pm EST 

Aeterna Zentaris Inc:Says the U.S. Food and Drug Administration (FDA) has accepted for filing the company's New Drug Application (NDA) for its ghrelin agonist, macimorelin acetate, in Adult Growth Hormone Deficiency (AGHD).Says the acceptance for filing of the NDA indicates the FDA has determined that the application is sufficiently complete to permit a substantive review. 

Company Quote

0.0025 +0.43%
24 Dec 2014